Evolution is an education program that focuses on the identification and management of patients with familial
hypercholesterolaemia (FH).
The program aims to increase awareness of FH amongst Australian specialists and provide efficacy and safety information about evolocumab, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor approved in
Australia for primary hypercholesterolaemia and homozygous familial hypercholesterolaemia (HoFH).
See attached flyer here for more information.
Professor Edward Janus graduated MB ChB from Otago University New Zealand and subsequently MD (Otago) for research on genetic causes of emphysema. He obtained his PhD in London studying lipoprotein metabolism in familial lipid disorders.
A National Heart Foundation of New Zealand Fellow, he became Professor in Clinical Biochemistry, University of Hong Kong 1992-97. He is currently Professor in the Department of Medicine University of Melbourne, Head of General Internal Medicine and Director of Research at Western Health.
Professor Janus' research interests are the epidemiology and prevention of diabetes and cardiovascular disease and in translating research into practice in the real world.
He is also:
Fellow of Royal Australasian College of Physicians and Fellow
of the Cardiac Society of Australia and New Zealand
President of the Board of the Australian Centre for Heart
Health in Melbourne. Treasurer of Asian Pacific Society of Atherosclerosis and Vascular
Diseases and Executive Board Member of the Asia Pacific Federation of International
Atherosclerosis Society.
Excellent Research Award 2007 from Government of Hong Kong,
China SAR.
No comments:
Post a Comment